The implementation of the EU Health Technology Assessment (HTA) regulation marks a pivotal shift in how clinical evidence is evaluated across Europe. With the regulation now in effect, pharmaceutical companies face both new opportunities and new responsibilities — particularly around the Joint Clinical Assessment (JCA), a centralized process for assessing the relative effectiveness and safety of new therapies.
In the Fall European Biopharmaceutical Review (EBR) Supplement Magazine, Pamela Vo, Vice President, HEOR, EVERSANA, offers a clear and practical overview of what this change means for manufacturers. Her article, “Strategic readiness for the EU HTA regulation: navigating the JCA landscape,” outlines the operational realities of the JCA and the strategic planning required to navigate it successfully.
Why should you read it?
- Understand the JCA’s impact on commercialization strategies in Europe.
- Learn how to align clinical development with HTA requirements to avoid costly missteps.
- Discover how EVERSANA’s cross-functional approach empowers pharma companies to meet tight timelines and diverse stakeholder expectations.
- Gain insights into national adaptations, including how countries like Germany are linking EU assessments with local reimbursement processes.
For companies preparing to launch in Europe, Pamela provides a grounded perspective on how to align clinical and regulatory strategies with evolving HTA expectations.
Read the full article on page 88.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…